Drug Profile
Trabedersen - Autotelic/Oncotelic Therapeutics
Alternative Names: AP 2/09-DS; AP-12009; AP-2/09; OT-101; OT-201; Personalised dosing TGF-beta antisense; TGF-beta antisenseLatest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Antisense Pharma
- Developer Autotelic; Mateon Therapeutics; Oncotelic; Oncotelic Therapeutics; Oncotelic Therapeutics - Dragon Overseas Capital (JV)
- Class Antineoplastics; Antisense oligonucleotides; Antivirals; Immunotherapies; Oligodeoxyribonucleotides; Thionucleotides
- Mechanism of Action Transforming growth factor beta2 inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Glioblastoma
- Phase II/III Malignant melanoma; Pancreatic cancer
- Phase II COVID 2019 infections; COVID-19 pneumonia
- Phase I Cancer
- Clinical Phase Unknown Non-small cell lung cancer
- Preclinical Diffuse intrinsic pontine glioma
- No development reported Colorectal cancer; Ovarian cancer
- Discontinued Anaplastic astrocytoma
Most Recent Events
- 04 Mar 2024 Phase-II/III clinical trials in Pancreatic cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) (IV) (NCT06079346)
- 17 Oct 2023 Oncotelic Therapeutics plans the phase IIb/III STOP-PC trial in Pancreatic cancer (Combination therapy, Second-line or greater therapy, Metastatic disease, Unresectable/Inoperable, Late stage disease) (IV) in December 2023 (NCT06079346)
- 23 May 2023 Oncotelic Therapeutics plans a phase IIb/III trial for Pancreatic cancer (Combination therapy, Second-line or greater therapy, Metastatic disease) in 2H of 2023